Key result
Higher serum MCP-1 levels were independently associated with good coronary collateral development in patients with stable angina pectoris (OR 1.01; 95% CI 1.002-1.019; P=0.014).
Why the study?
Is a higher serum MCP-1 level associated with better coronary collateral vessel development in patients with stable coronary artery disease?
Observational (n=83)
Is a higher serum MCP-1 level associated with better coronary collateral vessel development in patients with stable coronary artery disease?
Odds Ratio: 1.01 (95% CI 1.002–1.019)
p-value: p=0.014
Higher serum MCP-1 levels are independently associated with better coronary collateral development in patients with stable coronary artery disease.
BACKGROUND: The degree of coronary collateral development is not same in every patient with similar degree of coronary stenosis. In animal studies monocyte chemoattractant protein-1 (MCP-1) has been found to be related to collateral vessel development. In this study we investigated whether a higher serum MCP-1 level is related to better coronary collateral vessel development in patients with stable coronary artery disease. METHOD: Eighty-three patients with stable angina pectoris, who have at least one coronary stenosis equal to or greater than 70% at coronary angiography, were prospectively enrolled. Serum MCP-1 and vascular endothelial growth factor (VEGF) levels were studied. Coronary collateral development was graded according to the Rentrop method. Patients with grade 2-3 collateral developments were included in good collateral group and formed group I. The patients with grade 0-1 collateral developments were included in poor collateral group and formed group II. RESULTS: The serum MCP-1 level was significantly higher in good collateral group (288 ± 277 pg/ml vs. 132 ± 64 pg/ml; P<0.001). There was also a positive correlation between serum MCP-1 level and Rentrop score (r=0.39, P<0.001). The patients in the good collateral group also had a significantly higher number of coronary arteries with significant stenosis (1.7 ± 0.7 vs. 1.4 ± 0.6, P=0.049), and higher VEGF levels (322 ± 147 pg/ml vs. 225 ± 161 pg/ml, P=0.007). In multivariate analysis, only serum MCP-1 level (P=0.014, odds ratio: 1.01, 95% confidence interval: 1.002-1.019) was independently related to good coronary collateral development. CONCLUSION: Higher serum MCP-1 level is related to better coronary collateral development.
No takes yet. Share an insight, caveat, or question.
Şahinarslan et al. (2010) conducted an observational in Stable coronary artery disease (n=83). Serum monocyte chemoattractant protein-1 (MCP-1) vs. Lower serum MCP-1 levels was evaluated on Good coronary collateral development (Rentrop grade 2-3) (OR 1.01, 95% CI 1.002-1.019, p=0.014). Higher serum MCP-1 levels were independently associated with good coronary collateral development in patients with stable angina pectoris (OR 1.01; 95% CI 1.002-1.019; P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: